NASDAQ:MYNZ Mainz Biomed (MYNZ) Stock Price, News & Analysis $1.54 0.00 (0.00%) As of 09:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mainz Biomed Stock (NASDAQ:MYNZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mainz Biomed alerts:Sign Up Key Stats Today's Range$1.52▼$1.5250-Day Range$1.43▼$1.8052-Week Range$1.28▼$14.39Volume5,443 shsAverage Volume210,341 shsMarket Capitalization$8.34 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingHold Company Overview Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care. The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer. ColoAlert® has received CE marking for commercialization in Europe and is part of Mainz Biomed’s strategy to address gaps in current screening programmes by offering an alternative to traditional colonoscopy and immunochemical fecal occult blood tests. Founded as a spin-off from the Johannes Gutenberg University Mainz, Mainz Biomed has leveraged academic research in epigenetics to build a clinical pipeline focused on gastrointestinal cancers. The firm has established partnerships with clinical research centres and diagnostic laboratories across Europe, and it is conducting studies to support regulatory submissions in the United States. Through these collaborations, Mainz Biomed aims to validate its assays in diverse patient populations and support the integration of epigenetic testing into standard screening protocols. Led by a management team with deep experience in biotechnology, molecular diagnostics and regulatory affairs, Mainz Biomed continues to expand its product portfolio and broaden its geographic footprint. The company is pursuing additional indications beyond colorectal cancer and is investing in research and development to refine its platform for the early detection of other tumor types. As it advances clinical validation and navigates regulatory pathways, Mainz Biomed seeks to establish itself as a leader in epigenetic diagnostics and preventive oncology.AI Generated. May Contain Errors. Read More Mainz Biomed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreMYNZ MarketRank™: Mainz Biomed scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingMainz Biomed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialMainz Biomed has a consensus price target of $14.00, representing about 809.1% upside from its current price of $1.54.Amount of Analyst CoverageMainz Biomed has only been the subject of 1 research reports in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mainz Biomed are expected to grow in the coming year, from ($23.60) to ($9.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.25% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 5.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.25% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 5.29%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment-0.01 News SentimentMainz Biomed has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Mainz Biomed this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Read more about Mainz Biomed's insider trading history. Receive MYNZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYNZ Stock News HeadlinesMainz Biomed (NASDAQ:MYNZ) Trading Down 3% - Here's What HappenedOctober 9, 2025 | americanbankingnews.comMainz Biomed (NASDAQ:MYNZ) Trading Down 3% - What's Next?October 9, 2025 | americanbankingnews.comNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.October 15 at 2:00 AM | Brownstone Research (Ad)Mainz Biomed: Vielversprechende Studienergebnisse bei Bluttest für BauchspeicheldrüsenkrebsOctober 8, 2025 | de.investing.comMainz Biomed N.V. Reports Positive Results from Feasibility Study for Non-Invasive Pancreatic Cancer Screening TestOctober 8, 2025 | quiverquant.comQMainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectOctober 8, 2025 | globenewswire.comMainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee MeetingSeptember 30, 2025 | uk.finance.yahoo.comMainz Biomed Announces Commercial Launch of ColoAlert® in SwitzerlandSeptember 24, 2025 | markets.businessinsider.comSee More Headlines MYNZ Stock Analysis - Frequently Asked Questions How have MYNZ shares performed this year? Mainz Biomed's stock was trading at $4.32 at the beginning of the year. Since then, MYNZ shares have decreased by 64.4% and is now trading at $1.54. How were Mainz Biomed's earnings last quarter? Mainz Biomed NV (NASDAQ:MYNZ) released its earnings results on Tuesday, August, 15th. The company reported ($22.40) EPS for the quarter, missing analysts' consensus estimates of ($16.80) by $5.60. The business had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.25 million. When did Mainz Biomed's stock split? Shares of Mainz Biomed reverse split on Tuesday, December 3rd 2024.The 1-40 reverse split was announced on Friday, November 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Mainz Biomed IPO? Mainz Biomed (MYNZ) raised $10 million in an initial public offering (IPO) on Friday, November 5th 2021. The company issued 2,000,000 shares at $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Mainz Biomed? Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mainz Biomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mainz Biomed investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), Ford Motor (F), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD) and PayPal (PYPL). Company Calendar Last Earnings8/15/2023Today10/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MYNZ CIK1874252 Webmainzbiomed.com Phone49-6131-554-2860FaxN/AEmployees30Year Founded2021Price Target and Rating Average Price Target for Mainz Biomed$14.00 High Price Target$14.00 Low Price Target$14.00 Potential Upside/Downside+809.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.44 Current Ratio0.52 Quick Ratio0.43 Sales & Book Value Annual Sales$890 thousand Price / Sales9.36 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.59Miscellaneous Outstanding Shares5,410,000Free FloatN/AMarket Cap$8.33 million OptionableNot Optionable Beta0.25 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MYNZ) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.